Seer Centers of Excellence have the following key attributes:
At Biodesix our mission is to improve patient outcomes and lower healthcare costs by developing diagnostic solutions that may help reduce ineffective and unnecessary treatments. To help deliver on this mission we provide our biopharma partners with end-to-end diagnostic services inclusive of biomarker research, assay design and development, fit-for-purpose regulatory strategies, clinical trial testing, and diagnostic commercialization. Biodesix is known in the diagnostic industry as a leader in proteomics. We bring a wealth of knowledge in proteomics with over 15 years of experience, 5 on-market proteomic tests, and 2 additional proteomic tests in our pipeline.
Discovery Life Sciences is the global market leader in Biospecimen analysis, procurement, distribution, and Biomarker Services for the pharmaceutical, biotechnology, and diagnostics industries. HudsonAlpha Discovery is Discovery’s globally recognized sequencing and bioinformatics division that leverages the most current short and long read genomic analysis technologies to comprehensively support discovery, translational, and clinical research. Driven by science, the Discovery team engages with customers in an innovative, consultative approach to support the rapid acquisition and analysis of data to support decision making and the deployment of new innovations. We are Science at your Service™.
The Sanford Burnham Prebys Proteomics Core provides state-of-the-art mass spectrometry-based proteomics services including identification, quantification and characterization of proteins and their post-translational modifications. In addition to label-free global quantitative proteomic profiling, we also offer isobaric tagging technology such as TMT (up to 18 plex channels). The Proteomics Core is equipped with 5 mass-spectrometry platforms, automated liquid handling systems for sample preparation including the new Seer Proteograph platform, and a robust computational infrastructure and software. Currently staffed with 3 PhD-level scientists and seasoned research associates, we bring more than 20 years of experience in mass spectrometry and proteomics.
Soulbrain Holdings has been promoting the diversification of their business portfolio in in vitro diagnostics for the purpose of distribution of specialized reagents and point of care medical devices in parallel with investment in global companies proven to have competitive and disruptive technology in Life Science field. Soulbrain has secured a domestic Proteograph™ platform business with Seer by applying technology for broad-scale proteomic profiling, and will launch our premier services in Korea in Q122.
Evotec is one of the global leaders in providing drug discovery solutions on a stand-alone basis or through holistic, fully integrated drug discovery solutions. As part of Evotec’s industrialized high-throughput multi-omics platform EVOpanOmics, we are operating two of the best-equipped mass-spectrometry based proteomics facilities, with unprecedented throughput of >100,000 samples per year.
Unbiased proteomics allows identifying proteins that can serve as novel diagnostic or predictive biomarkers to enable patient stratification for personalized therapies. Evotec supports biomarker discovery from human clinical cohorts as well as from pre-clinical animal models and offers integrated bioinformatics services to leverage the full potential of your proteomics data. Together with our partners, we are expanding the use of Proteograph platform beyond serum and plasma proteomics to study cerebrospinal fluid (CSF), urine, secretome and other challenging biofluid specimen.